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Purpose: Cardiomyopathy is becoming the leading cause of death in patients with Duchenne muscular 
dystrophy because mechanically assisted lung ventilation and assisted coughing have helped resolve 
respiratory complications. To clarify cardiopulmonary function, we compared cardiac function between 
the home ventilator-assisted and non–ventilator-assisted groups. 
Methods: We retrospectively reviewed patients with Duchenne muscular dystrophy from January 2010 
to March 2016 at Gangnam Severance Hospital. Demographic characteristics, pulmonary function, and 
echocardiography data were investigated. 
Results: Fifty-four patients with Duchenne muscular dystrophy were divided into 2 groups: home 
ventilator-assisted and non–ventilator-assisted. The patients in the home ventilator group were older 
(16.25±1.85 years) than those in the nonventilator group (14.73±1.36 years) (P=0.001). Height, weight, 
and body surface area did not differ significantly between groups. The home ventilator group had a lower 
seated functional vital capacity (1,038±620.41 mL) than the nonventilator group (1,455±603.12 mL). 
Mean left ventricular ejection fraction and fractional shortening were greater in the home ventilator group, 
but the data did not show any statistical difference. The early ventricular filling velocity/late ventricular 
filling velocity ratio (1.7±0.44) was lower in the home ventilator group than in the nonventilator group 
(2.02±0.62). The mitral valve annular systolic velocity was higher in the home ventilator group (estimated 
β, 1.06; standard error, 0.48). Patients with Duchenne muscular dystrophy on a ventilator may have better 
systolic and diastolic cardiac functions.
Conclusion: Noninvasive ventilator assistance can help preserve cardiac function. Therefore, early 
utilization of noninvasive ventilation or oxygen may positively influence cardiac function in patients with 
Duchenne muscular dystrophy.
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Introduction 
Duchenne muscular dystrophy (DMD; Online Mendelian Inheritance in Man [OMIM] 
reference 310200) is an X-linked disease that affects 1 in 3,600–6,000 live male births.1) DMD 
is caused by a mutation in the dystrophin gene on chromosome Xp21.1, which contains 79 
exons of coding sequence and 2.5 Mb of DNA. The absence of expressed dystrophin leads to 
disruption of the cytoskeleton and loss of components of the cytoskeleton.2)
Patients with DMD are rarely symptomatic at birth and often show normal development 
until age 2 years. Thereafter, they show progressive muscle weakness, such as Gower’s sign, 
and lose ambulation at 7–12 years old. Untreated patients’ survival averages 20 years. The most 
common causes of mortality are respiratory and cardiac complications. Patients with DMD are 
at risk of respiratory complications as their condition deteriorates because of progressive loss 
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of respiratory muscle strength.3) Advances in the respiratory care of 
patients with DMD have improved their prognosis. Nocturnal home 
ventilators and mechanically assisted coughing lead to improved 
survival of patients with DMD.4,5) The American Thoracic Society 
has published a statement regarding the respiratory care of patients 
with DMD, including evaluation and management (i.e., respiratory 
muscle training, mechanical ventilation, corticosteroids, and end-
of-life care).6) These improvements in respiratory care make cardiac 
complications the leading cause of death in patients with DMD.7-11) 
Cardiac dysfunction in patients with DMD often manifests as 
cardiomyopathy or cardiac arrhythmia. Progression of cardiomyo-
pathy is the major cause of mortality. Cardiomyopathy can occur 
at any age but often occurs around 14–15 years.7,12) Angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor blockers, 
beta-blockers, or aldosterone antagonists are often used for mana-
gement of Duchenne cardiomyopathy and show improvements 
in cardiac function. Oral corticosteroid treatment can delay the 
onset of Duchenne cardiomyopathy.13) However, ap propriate phar-
macological management and the optimal time to start pharma-
cotherapy need further study.
Baseline assessment of cardiac function is needed for patients with 
DMD at diagnosis, and annual cardiac assessment is recommended 
for patients with DMD older than 10 years. Poor treatment outcomes 
have been seen in patients with DMD who fail to see a cardiologist 
after the onset of clinical symptoms of heart failure.3)
The degree of skeletal muscle weakness does not correlate with 
the severity of cardiomyopathy in patients with DMD. Thus, cardio-
pulmonary function relation theoretically may not be definite in 
patients with DMD. Therefore, we compared the cardiac function of 
the home ventilator group with the nonventilator group of patients 
with Duchenne muscular dystrophy.
Materials and methods
1. Patients
This was a retrospective, single-center study. We reviewed 54 pa-
tients with DMD who visited Gangnam Severance Hospital between 
January 2010 and February 2016. These patients were diagnosed 
with DMD by DMD gene mutation, the absence of dystrophin ex-
pression on muscle biopsy, or a phenotype consistent with DMD. 
Their age was 10–20 years, and they were all males. We divided 
the 54 patients into 2 groups: the home ventilator assistance group 
(n=24) and the nonventilator assistance group (n=30). The home 
ventilator was applied to DMD patients whose overnight sleep end-
tidal CO2 average is higher than 40 mmHg.  Among home ventilator 
assisted group, 21 patients needed overnight ventilator support, and 
3 patients needed continuous home ventilation.
2. Echocardiographic measurement and pulmonary function 
measurement
Echocardiographic measurements were obtained in both groups 
using a Siemens model ACUSON SC2000 (Siemens Medical Solu-
tions USA, Inc., Mountain View, CA, USA). Echocardiographic 
examinations were conducted according to the recommendations of 
the American Society of Echocardiography. On conventional echo-
cardiographic measurements, the left ventricular ejection fraction 
(LVEF) was measured using the M-mode and Simpson’s methods.
Pulmonary function tests are routinely performed by our pulmo-
nary rehabilitation center at least annually. These tests were per-
formed by acceptable spirometry. Sleep end-tidal CO2 average moni-
toring was done with SenTec digital monitoring system (SenTec AG 
group, Therwil, Switzerland).
3. Statistical analysis
All statistical analyses were made by using IBM SPSS Statistics 
ver. 22.0 (IBM Co., Armonk, NY, USA). We compared all demogra-
phic, echocardiographic, and pulmonary function factors of patients 
with DMD by independent t tests and multiple linear regression.
Results
We reviewed 54 cases of DMD divided into 2 groups based on 
their use of home respiratory assistance devices. The demographic 
characteristics of the 2 groups of patients with DMD are shown in 
Table 1. The mean age of patients in the home ventilator assisted 
group (16.25±1.85 years) was higher than that in the nonventilator 
assisted group (14.73±1.36 years) (P<0.001). Height, weight, and 
body surface area was not significantly different between the 2 
groups. 
Pulmonary function analysis data of the 2 groups is shown in 
Table 2. The home ventilator group (1,038±620.41 mL) had a lower 
seated functional vital capacity (FVC) than the nonventilator group 
(1,455±603.12 mL). Peak cough flow did not differ between the 2 
groups.
In nonventilator assisted group, 15 patients showed hypercapnia 
symptoms, and the most common symptoms are dyspnea and head-
ache followed by insomnia, daytime sleepness, fatigue, and anxiety. 
Table 1. Demographic characteristics of patients with Duchenne mus-
cular dystrophy 
Characteristic Nonventilator (n=30)
Home ventilator 
(n=24) P value
Age (yr) 14.73±1.36 16.25±1.85 0.001
Height (cm) 150.92±12.52 152.63±10.78 0.599
Weight (kg) 43.34±13.44 39.82±13.34 0.341
Body surface area (kg/m2) 18.85±4.87 16.88±4.59 0.137
Values are presented as mean±standard deviation.
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Among them, 13 patients showed symptoms improvements after 
applying home ventilator.
LVEF and fractional shortening (FS) showed slightly lower 
values in the nonventilator assistance group (ejection fraction [EF], 
50.62%±14.35%; FS, 26.15%±8.32%) than in the home ventilator 
assistance group (EF, 53.22%±12.97%; FS, 29.34%±8.87%) without 
statistical difference. The LVEF of both groups was lower than 55%, 
compatible with heart failure according to Canadian cardiovascular 
society guidelines.14) Neither interventricular wall thickness nor left 
ventricular posterior wall thickness showed hypertrophy in either 
group, without any statistical difference. The left ventricle dimension 
in diastole and systole did not show a difference between the 2 
groups, and there was no left ventricular dilatation. 
According to Doppler signals, the mitral inflow velocity did not 
show a statistical difference. However, the early ventricular filling 
velocity/late ventricular filling velocity ratio (2.02±0.62) was signifi-
cantly higher in the nonventilator assistance group than in the home 
ventilator assistance group (1.7±0.44) (P=0.03). The tissue Doppler 
velocities show no difference in early, late diastolic, or sys tolic peak 
mitral annuli velocity (E’, A’, S’). The E/E’ seemed to be within a 
reasonable range and did not show a statistical difference between 
the 2 groups (Table 3).
In a multiple linear regression model, tissue Doppler systolic S’ 
was higher in the home ventilator assistance group and lower in the 
nonventilator assistance group. This implied that the nonventilator 
assistance group demonstrated a relative decrease of the left ventri-
cle’s systolic function.15) Other conventional echocardiogra phic 
parameters did not show any statistical differences between the 2 
groups (Table 4).
Discussion
In DMD, the leading causes of death are pulmonary complications 
and cardiomyopathy. In the second decade of life, respiratory and 
cardiac muscle dysfunction substantially aggravates the disease and 
impairs the quality of life.16) Recently, pulmonary complications 
have been overcome by improvements in treatment, including home 
nocturnal ventilators and mechanically assisted coughing,4,5) and 
patients often present with cardiomyopathy, which is becoming the 
Table 2. Comparison of pulmonary function measurements
Measurement Nonventilator (n=30)
Home-ventilator 
(n=24) P value
Sitting FVC (mL)     1,455±603.12     1,038±620.41 0.024
PCF (mL) 231.57±98.86 195.56±76.02 0.196
Values are presented as mean±standard deviation.
FVC, forced vital capacity; PCF, peak cough flow.
Table 3. Comparison of echocardiographic measurements
Variable Nonventilator (n=30)
Home ventilator 
(n=24) P value
LV EF (%) 50.62±14.35 53.22±12.97 0.492
LV FS (%) 26.15±8.32 29.34±8.87 0.181
IVSTd (mm) 7.93±1.65 7.96±1.39 0.94
IVSTs (mm) 10.01±1.99 9.72±1.61 0.567
LVIDd (mm) 45.74±9.75 41.96±7.00 0.117
LVIDs (mm) 34.46±11.4 30.41±7.28 0.137
LV PWTd (mm) 6.65±1.12 6.24±1.22 0.206
LV PWTs (mm) 9.53±1.68 9.58±1.49 0.905
E (cm/sec) 83.3±16.29 82.83±18.20 0.921
A (cm/sec) 44.77±13.23 50.42±11.78 0.108
E/A 2.02±0.62 1.7±0.44 0.036
E' (cm/sec) 11.76±2.75 12.18±2.81 0.584
A' (cm/sec) 5.87±1.60 6.06±1.42 0.648
S' (cm/sec) 5.17±1.24 5.87±1.93 0.112
E/E' 7.39±2.32 7.07±1.82 0.581
Values are presented as mean±standard deviation.
LV, left ventricle; EF, ejection fraction; FS, fractional shortening; IVSTd, interven-
tricular septal thickness, diastole; IVSTs, interventricular septal thickness, 
systole; LVIDd, left ventricle internal diameter, diastole; LVIDs, left ventricle 
internal diameter, systole; PWTd, posterior wall thickness, diastole; PWTs, 
posterior wall thickness, systole; E, peak early mitral inflow velocity; A, peak late 
mitral inflow velocity; E’, peak early diastolic septal annulus velocity; A’, peak 
late diastolic septal annulus velocity; S’, peak systolic septal annulus velocity.
Table 4. Multiple linear regression analysis of echocardiographic mea-
surements
Independent variable Beta (standard error)* P value
LV EF (%) 3.94 (4.17) 0.349
LV FS (%) 3.03 (2.62) 0.254
IVSTd (mm) 0.21 (0.40) 0.608
IVSTs (mm) -0.38 (0.51) 0.464
LVIDd (mm) -3.56 (2.55) 0.169
LVIDs (mm) -4.15 (2.93) 0.162
LV PWTd (mm) -0.35 (0.36) 0.338
LV PWTs (mm) 0.03 (0.50) 0.959
E (cm/sec) 5.1 (5.01) 0.314
A (cm/sec) 7.59 (3.80) 0.051
E/A -0.27 (0.16) 0.095
E' (cm/sec) 1.19 (0.80) 0.143
A' (cm/sec) 0.29 (0.47) 0.543
S' (cm/sec) 1.06 (0.48) 0.032
E/E' -0.34 (0.66) 0.609
LV, left ventricle; EF, ejection fraction; FS, fractional shortening; IVSTd, interven-
tricular septal thickness, diastole; IVSTs, interventricular septal thickness, 
systole; LVIDd, left ventricle internal diameter, diastole; LVIDs, left ventricle 
internal diameter, systole; PWTd, posterior wall thickness, diastole; PWTs, 
posterior wall thickness, systole; E, peak early mitral inflow velocity; A, peak late 
mitral inflow velocity; E’, peak early diastolic septal annulus velocity; A’, peak 
late diastolic septal annulus velocity; S’, peak systolic septal annulus velocity.
*Beta (standard error) means comparing the strength of the effect of indepen-
dent variables between the 2 groups (nonventilator group, n=0; home ventilator 
group, n=1).
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oxygenation therapy so as not to subtly suppress the respiratory 
drive and exacerbate hypercapnia,3) the utilization of noninvasive 
ventilation or oxygen can benefit the cardiac function in patients 
with DMD. 
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